KLH-2109
Phase 3Small molecule
KLH-2109 is one of 46 small molecule programs targeting Endometriosis. It is currently in Phase 3.
1
Indications
7
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
IC-Green
PProvepharm SAS
Approved
Estrace
Novo NordiskApproved
Ketalar
AAultman Health Foundation
Approved
Implanon
OOrganon and Co
Approved
Catapres
Boehringer IngelheimApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Zocor
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometriosis5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KLH-2109. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKissei Pharmaceutical Co., Ltd.